Squamous cell carcinomas of the ovary: Report of four cases and literature review
Pathology Department, Areteion University Hospital, Athens Medical School, Athens, Greece.Clinical and experimental obstetrics & gynecology (Impact Factor: 0.42). 02/2005; 32(4):265-7.
Two cases of squamous cell carcinoma developing in mature cystic teratoma and two cases with a malignant change involving an ovarian epidermal cyst diagnosed in our institution over a 15-year-period are reported. This is a reminder that such changes may occur and issues regarding the problem of the differential diagnosis and management of these rare complications are discussed.
- [Show abstract] [Hide abstract]
ABSTRACT: Up to a quarter of ovarian masses originate from germ cells, and many of these are mature cystic teratomas. The secondary development of malignancy is a rare but well-known phenomenon in patients with ovarian teratomas. Squamous-cell carcinoma accounts for 80% of secondary malignant transformations of ovarian teratomas. We aimed to do an up-to-date systematic review of this rare malignant transformation. 64 suitable studies provided information on 277 patients. Squamous-cell carcinoma in mature cystic teratoma was mainly found in women aged more than 50 years, with high concentrations of squamous-cell-carcinoma antigen and cancer antigen CA125, and with ovarian tumours more than 100 mm in size. Patients with FIGO stage Ia tumours had better survival than those with more advanced disease. Complete resection together with hysterectomy, bilateral salpingo-oophorectomy and lymphadenectomy for patients with advanced disease, followed by adjuvant chemotherapy with an alkylating drug was associated with higher survival, radiotherapy was not. We make proposals for investigation and treatment of this rare disorder.The Lancet Oncology 01/2009; 9(12):1173-80. DOI:10.1016/S1470-2045(08)70306-1 · 24.69 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.